LGND LIGAND PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, LIGAND PHARMACEUTICALS INC reported revenue of $63.7M (up 33.7% from a year earlier), net income of $48.5M and diluted EPS of $2.22; over the last four quarters revenue was $291M and net income $197M; for the fiscal year ended December 2025 revenue was $268M, up 60.4% on the year before.
LGND annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $268M, gross profit n/a, operating income $41.0M, net income $124M (margin 46.4%), EPS $6.13
- Fiscal year ended Dec 2024: revenue $167M, gross profit n/a, operating income −$22.6M, net income −$4.03M (margin -2.4%), EPS −$0.22
- Fiscal year ended Dec 2023: revenue $131M, gross profit n/a, operating income $11.9M, net income $52.2M (margin 39.7%), EPS $2.94
- Fiscal year ended Dec 2022: revenue $196M, gross profit n/a, operating income $3.04M, net income −$33.4M (margin -17.0%), EPS −$1.98
- Fiscal year ended Dec 2021: revenue $242M, gross profit n/a, operating income $104M, net income $57.1M (margin 23.7%), EPS $3.31
LGND quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $63.7M (up 33.7% year over year), net income $48.5M, EPS $2.22
- Quarter ended Mar 31, 2026: revenue $51.7M (up 14.1% year over year), net income −$13.3M, EPS −$0.67
- Quarter ended Dec 31, 2025 (from the annual report): revenue $59.7M (up 39.4% year over year), net income $44.8M, EPS $2.42
- Quarter ended Sep 30, 2025: revenue $115M (up 122.8% year over year), net income $117M, EPS $5.68
- Quarter ended Jun 30, 2025: revenue $47.6M (up 14.7% year over year), net income $4.85M, EPS $0.24
- Quarter ended Mar 31, 2025: revenue $45.3M (up 46.3% year over year), net income −$42.5M, EPS −$2.21
- Quarter ended Dec 31, 2024 (from the annual report): revenue $42.8M (up 52.4% year over year), net income −$31.1M, EPS −$1.70
- Quarter ended Sep 30, 2024: revenue $51.8M (up 57.6% year over year), net income −$7.17M, EPS −$0.39
- Quarter ended Jun 30, 2024: revenue $41.5M (up 57.5% year over year), net income −$51.9M, EPS −$2.88
- Quarter ended Mar 31, 2024: revenue $31.0M (down 29.6% year over year), net income $86.1M, EPS $4.75
- Quarter ended Dec 31, 2023 (from the annual report): revenue $28.1M (down 44.2% year over year), net income $18.2M, EPS $1.07
- Quarter ended Sep 30, 2023: revenue $32.9M (down 44.5% year over year), net income −$10.3M, EPS −$0.59
- Quarter ended Jun 30, 2023: revenue $26.4M (down 47.4% year over year), net income $2.29M, EPS $0.13
- Quarter ended Mar 31, 2023: revenue $44.0M (up 20.4% year over year), net income $41.9M, EPS $2.33
- Quarter ended Dec 31, 2022: revenue $50.4M (down 10.7% year over year), net income −$17.5M, EPS −$1.04
- Quarter ended Sep 30, 2022: revenue $59.2M (down 0.8% year over year), net income $404K, EPS $0.02
- Quarter ended Jun 30, 2022: revenue $50.1M (down 36.4% year over year), net income −$895K, EPS −$0.05
- Quarter ended Mar 31, 2022: revenue $36.5M (down 21.6% year over year), net income −$15.4M, EPS −$0.91
- Quarter ended Dec 31, 2021: revenue $56.4M, net income −$5.42M, EPS −$0.33
- Quarter ended Sep 30, 2021: revenue $59.7M, net income $13.7M, EPS $0.80
LGND cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $49.4M, share buybacks $15.0M
- Fiscal year ended Dec 2024: operating cash flow $97.0M, share buybacks $0
- Fiscal year ended Dec 2023: operating cash flow $49.6M, share buybacks $0
- Fiscal year ended Dec 2022: operating cash flow $138M, share buybacks $0
- Fiscal year ended Dec 2021: operating cash flow $78.8M, share buybacks $0
LGND balance sheet
- Jun 30, 2026: cash $1.01B, total assets $2.19B, total liabilities $1.22B, shareholders' equity $968M
- Mar 31, 2026: cash $115M, total assets $1.53B, total liabilities $535M, shareholders' equity $997M
- Dec 31, 2025: cash $175M, total assets $1.56B, total liabilities $543M, shareholders' equity $1.02B
- Sep 30, 2025: cash $139M, total assets $1.48B, total liabilities $527M, shareholders' equity $950M
- Jun 30, 2025: cash $67.7M, total assets $949M, total liabilities $120M, shareholders' equity $827M
- Mar 31, 2025: cash $48.0M, total assets $905M, total liabilities $110M, shareholders' equity $796M
- Dec 31, 2024: cash $72.3M, total assets $942M, total liabilities $111M, shareholders' equity $830M
- Sep 30, 2024: cash $63.6M, total assets $955M, total liabilities $114M, shareholders' equity $841M
What is LGND's revenue?
LIGAND PHARMACEUTICALS INC reported $291M of revenue over its last four quarters, through June 30, 2026.
Is LGND profitable?
Yes. LIGAND PHARMACEUTICALS INC earned $197M over the last four quarters.
What is LGND's EPS?
Diluted earnings per share over the last four quarters were $9.65; $2.22 in the latest quarter.